Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

629 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models.
Capello M, Cappello P, Linty FC, Chiarle R, Sperduti I, Novarino A, Salacone P, Mandili G, Naccarati A, Sacerdote C, Beghelli S, Bersani S, Barbi S, Bassi C, Scarpa A, Nisticò P, Giovarelli M, Vineis P, Milella M, Novelli F. Capello M, et al. Among authors: milella m. J Hematol Oncol. 2013 Sep 6;6:67. doi: 10.1186/1756-8722-6-67. J Hematol Oncol. 2013. PMID: 24010981 Free PMC article. Clinical Trial.
Autoantibody signature in human ductal pancreatic adenocarcinoma.
Tomaino B, Cappello P, Capello M, Fredolini C, Ponzetto A, Novarino A, Ciuffreda L, Bertetto O, De Angelis C, Gaia E, Salacone P, Milella M, Nisticò P, Alessio M, Chiarle R, Giuffrida MG, Giovarelli M, Novelli F. Tomaino B, et al. Among authors: milella m. J Proteome Res. 2007 Oct;6(10):4025-31. doi: 10.1021/pr070281a. Epub 2007 Sep 8. J Proteome Res. 2007. PMID: 17824682
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen.
Cappello P, Tomaino B, Chiarle R, Ceruti P, Novarino A, Castagnoli C, Migliorini P, Perconti G, Giallongo A, Milella M, Monsurrò V, Barbi S, Scarpa A, Nisticò P, Giovarelli M, Novelli F. Cappello P, et al. Among authors: milella m. Int J Cancer. 2009 Aug 1;125(3):639-48. doi: 10.1002/ijc.24355. Int J Cancer. 2009. PMID: 19425054 Free article.
Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer.
Tomaino B, Cappello P, Capello M, Fredolini C, Sperduti I, Migliorini P, Salacone P, Novarino A, Giacobino A, Ciuffreda L, Alessio M, Nisticò P, Scarpa A, Pederzoli P, Zhou W, Petricoin Iii EF, Liotta LA, Giovarelli M, Milella M, Novelli F. Tomaino B, et al. Among authors: milella m. J Proteome Res. 2011 Jan 7;10(1):105-12. doi: 10.1021/pr100213b. Epub 2010 Jun 10. J Proteome Res. 2011. PMID: 20455595 Free article.
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Vaccaro V, Sperduti I, Milella M. Vaccaro V, et al. Among authors: milella m. N Engl J Med. 2011 Aug 25;365(8):768-9; author reply 769. doi: 10.1056/NEJMc1107627. N Engl J Med. 2011. PMID: 21864184 No abstract available.
Molecular and genetic bases of pancreatic cancer.
Vaccaro V, Gelibter A, Bria E, Iapicca P, Cappello P, Di Modugno F, Pino MS, Nuzzo C, Cognetti F, Novelli F, Nistico P, Milella M. Vaccaro V, et al. Among authors: milella m. Curr Drug Targets. 2012 Jun;13(6):731-43. doi: 10.2174/138945012800564077. Curr Drug Targets. 2012. PMID: 22458519 Free article. Review.
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M. Vaccaro V, et al. Among authors: milella m. World J Gastroenterol. 2013 Jul 28;19(28):4511-9. doi: 10.3748/wjg.v19.i28.4511. World J Gastroenterol. 2013. PMID: 23901226 Free PMC article. Clinical Trial.
629 results